Securities law
Dermata Therapeutics Faces Nasdaq Delisting Following Failure to Meet Stockholder's Equity Requirement and Minimum Bid Price Requirement
Dermata Therapeutics, Inc. has found itself in a precarious position as it struggles to comply with the minimum stockholders' equity requirement and minimum bid price requirement to maintain its listing on the Nasdaq Capital Market. The company received a notice from the Nasdaq Listing Qualifications Department indicating that it